Trademark Snap Shot Amendment & Mail Processing Stylesheet (Table presents the data on Amendment & Mail Processing Complete) |
|||
OVERVIEW |
|||
SERIAL NUMBER | 88073859 | FILING DATE | 08/10/2018 |
REG NUMBER | 0000000 | REG DATE | N/A |
REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
INTL REG # | N/A | INTL REG DATE | N/A |
TM ATTORNEY | AVENT, TEAGUE A |
L.O. ASSIGNED | N70-NOT FOUND |
PUB INFORMATION |
|||
RUN DATE | 01/17/2020 | ||
PUB DATE | N/A | ||
STATUS | 661-RESPONSE AFTER NON-FINAL-ACTION-ENTERED | ||
STATUS DATE | 01/16/2020 | ||
LITERAL MARK ELEMENT | AB CHECK | ||
DATE ABANDONED | N/A | DATE CANCELLED | N/A |
SECTION 2F | NO | SECTION 2F IN PART | NO |
SECTION 8 | NO | SECTION 8 IN PART | NO |
SECTION 15 | NO | REPUB 12C | N/A |
RENEWAL FILED | NO | RENEWAL DATE | N/A |
DATE AMEND REG | N/A |
FILING BASIS |
|||||
FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
1 (b) | YES | 1 (b) | YES | 1 (b) | NO |
44D | NO | 44D | NO | 44D | NO |
44E | NO | 44E | NO | 44E | NO |
66A | NO | 66A | NO | ||
NO BASIS | NO | NO BASIS | NO |
MARK DATA |
|
STANDARD CHARACTER MARK | NO |
LITERAL MARK ELEMENT | AB CHECK |
MARK DRAWING CODE | 3-AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/LETTER(S)/NUMBER(S) |
COLOR DRAWING FLAG | NO |
CURRENT OWNER INFORMATION |
|
PARTY TYPE | 10-ORIGINAL APPLICANT |
NAME | AbCheck s.r.o. |
ADDRESS | Vedeckotechnicky Park Plzen Teslova 3 Plzen, 30100 |
ENTITY | 16-LTD LIAB CO |
CITIZENSHIP | Czech Republic |
GOODS AND SERVICES |
|
INTERNATIONAL CLASS | 001 |
DESCRIPTION TEXT | Chemicals, in particular biochemical preparations, reagents, laboratory reagents, binding molecules, peptide or antibody libraries or peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and research purposes, for use in molecular biology, in particular for the identification and characterisation of molecules, in particular proteins, enzymes and nucleic acids |
INTERNATIONAL CLASS | 005 |
DESCRIPTION TEXT | Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of binding molecules, peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences coding for these molecules for treating infectious, inflammatory and tumorigenic diseases; preparations for therapeutic purposes, in particular human medicine purposes, diagnostic purposes, therapy or diagnosis of infectious, inflammatory and tumorigenic diseases |
INTERNATIONAL CLASS | 042 |
DESCRIPTION TEXT | Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody discovery, namely in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to screening of antibody libraries, namely in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely scientific research in the field of antibody research and antibody optimization |
GOODS AND SERVICES CLASSIFICATION |
|||||||
INTERNATIONAL CLASS | 001 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
INTERNATIONAL CLASS | 042 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
CHANGE IN REGISTRATION | NO |
COLORS CLAIMED STATEMENT | Color is not claimed as a feature of the mark. |
DISCLAIMER W/PREDETER TXT | "AB" OR "CHECK" |
DESCRIPTION OF MARK | The mark consists of letters "AB" and "CHECK" separated by an array of circles. |
PROSECUTION HISTORY |
||||
DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
01/16/2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 016 |
01/15/2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 015 |
01/15/2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 014 |
07/17/2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 013 |
07/17/2019 | GNRT | O | NON-FINAL ACTION E-MAILED | 012 |
07/17/2019 | CNRT | R | NON-FINAL ACTION WRITTEN | 011 |
06/13/2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 010 |
06/13/2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 009 |
06/13/2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 008 |
01/02/2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 007 |
01/02/2019 | GNRT | F | NON-FINAL ACTION E-MAILED | 006 |
01/02/2019 | CNRT | R | NON-FINAL ACTION WRITTEN | 005 |
11/28/2018 | DOCK | D | ASSIGNED TO EXAMINER | 004 |
08/21/2018 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | 003 |
08/18/2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 002 |
08/14/2018 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
ATTORNEY | Karen L. Elbing |
CORRESPONDENCE ADDRESS | Karen L. Elbing CLARK+ELBING LLP 101 FEDERAL STREET, 15TH FLOOR BOSTON MA 02110 |
DOMESTIC REPRESENTATIVE | NONE |